Fibrinolytic activity of 6-keto-prostaglandin E₁KORBUT, R; BYRSKA-DANEK, A; GRYGLEWSKI, R. J et al.Thrombosis and haemostasis. 1983, Vol 50, Num 4, issn 0340-6245, 893Article

A study of the fibrin plate assay of fibrinolytic agents: optimal conditions, reproducibility and precisionJESPERSEN, J; ASTRUP, T.Haemostasis. 1983, Vol 13, Num 5, pp 301-315, issn 0301-0147Article

Thrombolytic therapy: current status. (first of two parts)MARDER, V. J; SHERRY, S.The New England journal of medicine. 1988, Vol 318, Num 23, pp 1512-1520, issn 0028-4793Article

Antistreptokinase titres after intravenous streptokinaseJALIHAL, S; MORRIS, G. K.Lancet (British edition). 1990, Vol 335, Num 8683, pp 184-185, issn 0140-6736, 2 p.Article

Effects of Thrombolytic Agents on Tympanostomy Tubes Occluded by Blood ClotsORESTES, Michael I; FILETA, Bader; HAYMES, Snezana et al.Archives of otolaryngology, head & neck surgery. 2011, Vol 137, Num 12, pp 1228-1231, issn 0886-4470, 4 p.Article

Thrombolytic therapy in a community hospitalSPITZER, S; CARVER, J. R; PARRIS, T. M et al.Practical cardiology. 1991, Vol 17, Num 2, pp 48-50, issn 0361-3372, 3 p.Article

Effect of a new antithrombotic agent (defibrotide) in acute renal failure due to thrombotic microangiopathyBONOMINI, V; FRASCA, G. M; RAIMONDI, C et al.Nephron. 1985, Vol 40, Num 2, pp 195-200, issn 0028-2766Article

Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humansVERSTRAETE, M; BOUNAMEAUX, H; DE COCK, F et al.The Journal of pharmacology and experimental therapeutics. 1985, Vol 235, Num 2, pp 506-512, issn 0022-3565Article

Klinische Erfahrungen bei der Urokinase-Behandlung = Expérience clinique de l'urokinase = Clinical experience with the Urokinase therapyTILSNER, V.Arzneimittel-Forschung. 1984, Vol 34, Num 1, pp 55-61, issn 0004-4172Article

Human tissue-type plasminogen activator: from the laboratory to the bedsideCOLLEN, D.Circulation (New York, N.Y.). 1985, Vol 72, Num 1, pp 18-20, issn 0009-7322Article

Induction of a sustained fibrinolytic response by BRL 26921 in vitroFEARS, R; GREEN, J; SMITH, R. A. G et al.Thrombosis research. 1985, Vol 38, Num 3, pp 251-260, issn 0049-3848Article

FIBRINOLYSIS BY BILEKING JB.1972; THROMBOSIS DIATHESIS HAEMORRHAG.; ALLEM.; DA. 1972; VOL. 28; NO 2; PP. 299-305; ABS. FR. ALLEM.; BIBL. 6REF.Serial Issue

PREPARATION AND PROPERTIES OF ADDUCTS OF STREPTOKINASE AND STREPTOKINASE-PLASMIN COMPLEX WITH POLYETHYLENE GLYCOL AND PLURONIC POLYOL F38NEWMARK J; ABUCHOWSKI A; MURANO G et al.1982; JOURNAL OF APPLIED BIOCHEMISTRY; ISSN 0161-7354; USA; DA. 1982; VOL. 4; NO 2; PP. 185-189; BIBL. 23 REF.Article

STATISTICAL PROBLEMS IN THE DESIGN OF CLINICAL TRIALS AND INTERPRETATION OF RESULTS = PROBLEMES STATISTIQUES DANS L'ELABORATION D'ESSAIS CLINIQUES ET INTERPRETATION DES RESULTATSSHAW LW; CORNFIELD J; COLE CM et al.1974; THROMBOSIS DIATHESIS HAEMORRHAG., SUPPL.; ALLEM.; DA. 1974; NO 59; PP. 191-202; BIBL. 5REF.; (THROMB. PATHOG. CLIN. TRIALS. TRANS. IV. INT. CONGR. THROMB. HAEMOSTASIS; VIENNA, AUSTRIA; 1973)Conference Paper

2.134.435 (B) (7214422). - 24 AVRIL 1972. DERIVES ACTIFS DU BENZOFURANNE, COMPOSITIONS THERAPEUTIQUES LES CONTENANT ET PROCEDES DE PREPARATION DE CES DERIVES ET COMPOSITIONSsdPatent

A FIBRINOLYTIC AGENT FROM A SATURNID CATERPILLAR. PARTIAL PURIFICATION AND CHARACTERIZATION = UN AGENT FIBRINOLYTIQUE A PARTIR D'UNE CHENILLE SATURNIDE. PURIFICATION PARTIELLE ET CARACTERISATIONAROCHA PINANGO CL; MARSH NA; ROBINSON D et al.1973; THROMBOSIS DIATHESIS HAEMORRAG.; ALLEM.; DA. 1973; VOL. 29; NO 1; PP. 135-142; ABS. FR. ALLEM.; BIBL. 1P.Serial Issue

Use of streptokinase for the salvage of a free flap: case report and review of the use of thrombolytic therapyCHUBERT, W; HUNTER, D. W; GUZMAN-STEIN, G et al.Microsurgery. 1987, Vol 8, Num 3, pp 117-121, issn 0738-1085Article

The hematologic consequences of thrombolytic therapyFLETCHER, A. P; ALKJAERSIG, N. K.Progress in hematology. 1986, Vol 14, pp 183-200, issn 0079-6301Article

The fibrinolytic action of flufenamate and its influence on plasminogen binding to fibrinCHEVALLET-PRANDINI, M. H; CHAPEL, A; SUSCILLON, M et al.Thrombosis research. 1985, Vol 38, Num 5, pp 481-489, issn 0049-3848Article

Laboratory control of urokinase therapy at low or moderate dosages: an in-vitro studyMUSUMECI, V; ZAPPACOSTA, B; CARUSO, A et al.Haemostasis. 1983, Vol 13, Num 5, pp 316-321, issn 0301-0147Article

Clinical experience with tissue plasminogen activator stored at -20°CGREWING, R; MESTER, U; LÖW, M et al.Ophthalmic surgery. 1992, Vol 23, Num 11, pp 780-781, issn 0022-023XArticle

Ancrod causes rapid thrombolysis in patients with acute strokePOLLAK, V. E; GLAS-GREENWALT, P; OLINGER, C. P et al.The American journal of the medical sciences. 1990, Vol 299, Num 5, pp 319-325, issn 0002-9629Article

Rise of plasma t-PA fibrinolytic activity in a group of maturity onset diabetic patients shifted from a first generation (tolbutamide) to a second generation sulphonylurea (gliclazide)GRAM, J; KOLD, A; JESPERSEN, J et al.Journal of internal medicine. 1989, Vol 225, Num 4, pp 241-247, issn 0954-6820, 7 p.Article

Rationale for the development of antithrombotic, antimetastatic and fibrinolytic durgs: a mechanic point of view, international workshop, Montebello PQ, Canada, April 28-May 1, 1987BASTIDA, E. Ed; BUCHANAN, M. R; OFOSU, F. A et al.Seminars in thrombosis and hemostasis. 1988, Vol 14, Num 1, pp 1-132, issn 0094-6176Conference Proceedings

Thrombolytic therapy in renal vein thrombosisHARRINGTON, J. T.Archives of internal medicine (1960). 1984, Vol 144, Num 1, pp 33-34, issn 0003-9926Article